CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

filgotinib

Last Updated: October 9, 2020
Result type: Reports
Project Number: SR0656-000
Product Line: Reimbursement Review

Generic Name: filgotinib

Brand Name: TBC

Manufacturer: Gilead Sciences Canada, Inc.

Therapeutic Area: Arthritis, Rheumatoid

Indications: Indicated as monotherapy, or in combination with methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), for reducing signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.

Manufacturer Requested Reimbursement Criteria1: Indicated as monotherapy, or in combination with methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), for reducing signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.

Submission Type: Initial

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJuly 06, 2020
Call for patient input closedAugust 25, 2020
Clarification:

- Patient input submission received from the Arthritis Society & Canadian Arthritis Patient Alliance

Submission receivedAugust 04, 2020